The combination of these novel anti-CEA and anti-EpCAM RevTMs with the Dual-RevCAR T cell platform allowed us to achieve a true AND-gate combinatorial targeting of CRC cells. The gene discussed is EPCAM; the disease is colorectal carcinoma.